Headquarters office near Boston, MA USA.
Production facilities, laboratories and R&D center in Santiago, Chile.
Plantation of quillaja saponaria clones rich in saponins content in Los Angeles, Chile.
High Pressure Liquid Chromatography (HPLC) pharmaceutical GMP capabilities with industrial scale including quality control of raw materials and finish products on site.
State of the art R&D laboratories and pilot plants to scale up new developments.
Pharmaceutical GMP production facilities.
Quillaja saponaria
Sustainable Supply Chain
Q-VANT has developed a strong raw material supply chain created over the past 12 years with more than ten quillaja plant material suppliers located in four regions of Chile.
All of Q-VANT’s raw materials are sustainably harvested with continuous batch-to-batch quality control and assurance.
In addition, Q-VANT has invested and implemented strong forestry R&D that has resulted in unique clones of quillaja saponaria trees with high saponin content.
Q-VANT is also investing in plant cell technology to further enhance our sustainable supply capabilities and capacities.
Quality Management Policy
Currently, there is a global environment where the requirements and standards for the provision of quality products to the population grow exponentially. Governments and cross-cutting entities that advocate for Public Health establish these requirements to ensure the commitment of organizations to meet quality standards. Under this scenario, at Q-VANT we seek to comply with the health environment that commits actors from the public, private and academic spheres to contribute positively to society.
The quality of raw materials is essential to ensure that the highest regulatory standards are met in relation to the production of vaccines to take care of the health of the population. Our mission is to ensure a reliable supply of Quillaja-based saponin precursors and adjuvants, to be used in human and animal vaccines developed to combat diseases and pandemics worldwide. Therefore, we are committed to achieving high levels of quality in our processes to produce and supply the vaccine adjuvant market by complying with regulatory requirements and those of our customers nationally and internationally.
Consequently, we will maintain objectives that allow us to periodically evaluate the performance of our Quality Management System, and that these help us to promote the continuous improvement of the organization.